June 12, 2018 Newport Coast CA – VivoSense (Vivonoetics), the leading
provider of visualization and analysis software for data from wearable
sensors is excited to announce the release of VivoSense®️ 3.2.

With the accelerating adoption of wearable physiological sensors, large
complex clinical trial data sets are being generated across a wide variety
patient populations and disease states, including rare diseases.
VivoSense® 3.2 provides the most rigorous analyses of these data
possible in providing the endpoints and biomarkers which withstand
Regulatory scrutiny and academic oversight.

As a company VivoSense is committed to providing robust clinical
endpoints for industry leading biotechnology, pharma, CROs and
healthcare providers including Roche, Mayo Clinic, Nationwide Children’s
Hospital and Harvard University.